Analyses of PBMCs and tumors revealed that Mw treatment was associated with an increase in CD4+ and CD8+ T cells in both PBMC and tumor infiltrating lymphocytes along with a significant decrease in expression of the immunosuppressive markers FoxP3 and PD-1 353. The gene discussed is CD8A; the disease is neoplasm.